Effective December 24, 2024, Genenta Science S.p.A. and AGC Biologics S.p.A. entered into the Second Amendment to their Development and Master Services Agreement. This amendment significantly strengthens their partnership for the manufacturing of Genenta's cell therapy products.
The agreement now includes the reservation of an exclusive GMP (Good Manufacturing Practice) suite dedicated solely to Genenta's benefit at AGC Biologics' Cell and Gene Center of Excellence in Milan. Additionally, AGC Biologics will commit a specified number of full-time equivalent employees to Genenta's manufacturing operations.
This strategic move enhances Genenta's production capabilities, ensuring compliance with cGMP standards and improving efficiency and reliability in its manufacturing processes. Securing dedicated manufacturing capacity is crucial for advancing Genenta's clinical trials and preparing for the potential commercialization of its cell-based therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.